Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variable dosing regimens of intravitreal conbercept for diabetic macular edema
ChiCTR1900022572Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jun 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in diabetic macular edema (DME) (3 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Best corrected visual acuity and Optical coherence tomography. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR1900022572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022572.